NCT06014762 - P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2041

Conditions

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh-grade B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Transformed Follicular Lymphoma (tFL)Follicular Lymphoma Grade 3BDLBCLDLBCL - Diffuse Large B Cell LymphomaDLBCL Arising From Follicular LymphomaDLBCL, Diffused Large B Cell LymphomaDLBCL NOS

Interventions

BIOLOGICAL

P-CD19CD20-ALLO1

Single weight-based IV administration

DRUG

Rimiducid

Single weight-based IV administration

Trial Locations (14)

10016

RECRUITING

NYU Grossman School of Medicine, New York

27599

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

29605

RECRUITING

Prisma Health - Upstate Cancer Institute, Greenville

32803

RECRUITING

Advent Health Orlando, Orlando

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

45206

RECRUITING

University of Cincinnati, Cincinnati

46202

RECRUITING

Indiana University, Indianapolis

48201

RECRUITING

Wayne State - Karmanos Cancer Institute, Detroit

70808

RECRUITING

Our Lady of the Lake Hospital, Baton Rouge

73104

RECRUITING

University of Oklahoma, Health Sciences Center, Oklahoma City

75204

RECRUITING

Baylor Scott & White Research Institute, Dallas

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

92093

RECRUITING

University of California San Diego, La Jolla

92354

RECRUITING

Loma Linda University Cancer Center, Loma Linda